Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KYMRIAH 1.2 x 106 – 6 x 108 cells (tisagenlecleucel) dispersion for infusion is substantial in the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
|
Clinical Added Value
| moderate |
Considering:
- the updated efficacy data from the ELIANA clinical study, confirming the results previously analysed, particularly in terms of complete remission percentage, with this remission remaining durable in some patients (approximately 1/3 to 1/2), following a median follow-up of 79.1 months between injection of KYMRIAH (tisagenlecleucel) and the database freeze for this last analysis in the ELIANA study,
- the overall survival results, with a median of 47.9 months (CI95% [19.4; NE]) in the 97 patients included (ITT population) in ELIANA, in clinical situations that are life-threatening in the short term and for which the available treatment options do not enable a complete recovery to be envisaged,
- the safety profile marked by significant short-term toxicity,
- additional experience with respect to the real-world data in the DESCAR-T registry (median follow-up duration since eligibility of 19.4 months, 19 activated centres, 99 patients treated with KYMRIAH (tisagenlecleucel)), suggesting results consistent with those of the clinical studies,
- despite the initial uncertainties identified, which persist, particularly with respect to:
- the exact effect size compared to therapeutic management, in the absence of any robust comparison,
- the qualitative weakness of the data in the DESCAR-T registry (data not monitored),
- maintenance of the clinical efficacy in the long term, particularly concerning achievement of full recovery for patients in lasting remission,
- and the absence of long-term safety data,
The Committee considers that its previous conclusions are not liable to be modified. On the basis of currently available data, KYMRIAH 1.2 x 106 – 6 x 108 cells (tisagenlecleucel) dispersion for infusion still provides a moderate clinical added value (CAV III) in the care pathway for the treatment of paediatric and young adult patients with B-cell ALL that is refractory, in relapse post-transplant or in second or later relapse.
|
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
NCL9WRScg6UzHn1r